Stockreport

Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral [Yahoo! Finance]

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF Law upgraded the stock's rating to Buy from Neutral, with a share price target of $67. The adjustment followed promising results from a trial investigating the impact [Read more]